China Resources Boya Bio-pharmaceutical Group News

Morgan Stanley Starts China Resources Boya Bio-pharmaceutical Group at Equal-weight; Price Target Is 37 Yuan

MT NewswiresMay 27 12:13

Liberal Arts Biotech (300294): Focus on the main business, the expansion of lightweight upper-array plasma stations can be expected in the future

華安證券May 26 00:00

Liberal Arts Biotech (300294): Relying on the majority shareholder, China Resources Pharmaceutical's pulp harvesting station has a large epitaxial space

華源證券May 23 00:00

Liberal Arts Biotech (300294): Focus on the main business, the expansion of lightweight upper-array plasma stations can be expected in the future

華安證券May 21 20:56

Liberal Arts Biotech (300294): Steady management of the blood products business, spin-off of the non-blood products business and lightweight launch

中信建投證券Apr 30 13:46

Liberal Arts Biotech (300294): Performance is in line with expectations, profitability improved significantly

東北證券Apr 30 00:00

Liberal Arts Biotech (300294): Performance is in line with expectations, optimistic about the company's future growth space

廣發證券Apr 25 18:16

China Post Securities released a research report on April 25 stating that it gave Liberal Arts Biotech (300294.SZ) a purchase rating. The main reasons for the rating include: 1) blood products are expected to maintain good growth, and the amount of pulp c

Zhitong FinanceApr 25 09:25

Liberal Arts Biotech (300294): Divestment of a subsidiary focusing on blood products led to fluctuations in performance

中金公司Apr 24 08:21

Liberal Arts Biotech (300294): First-quarter results are in line with expectations, annual pulp harvesting is expected to increase at an accelerated pace

中郵證券Apr 24 00:00

Liberal Arts Biotech (300294): Steady growth in blood products focuses on achieving breakthroughs in the main business

華鑫證券Apr 17 00:00

Liberal Arts Biotech (300294): Actively expand plasma supply and divest the non-blood products business and launch a lightweight business

海通證券Apr 13 00:00

Liberal Arts Biotech (300294): Steady growth in blood products business, impairment of goodwill affects apparent profit

廣發證券Apr 2 00:00

Liberal Arts Biotech (300294): Steady growth in blood products business continues to focus on main business development

中信建投證券Mar 29 00:00

Liberal Arts Biotech (300294): Blood products business is growing steadily, and the product echelon continues to be rich

光大證券Mar 28 00:00

Liberal Arts Biotech (300294): Steady growth in the blood products business, gradually promoting the divestment of the non-blood business

中金公司Mar 26 16:12

Commentary on the 2023 Annual Report of Liberal Arts Biotech (300294): Continued focus on the core business of blood products to strengthen plasma station resource expansion and acquisition integration

西部證券Mar 24 00:00

Liberal Arts Biotech (300294): Performance meets expectations and continues to focus on blood products business

中金公司Nov 3, 2023 07:37

Liberal Arts Biology (300294): Another breakthrough in plasma station resources, gradual divestment of non-blood products business

中信建投證券Nov 2, 2023 14:27

Liberal Arts Biology (300294): Actively promoting the establishment of new plasma stations focusing on the development of blood products business

廣發證券Oct 31, 2023 00:00